Medigene AG / Medigene participates at five national and international conferences . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 26 September 2016. Medigene AG (http://www.medigene.de) (MDG1, Frankfurt, Prime Standard) announces its participation at five upcoming national and international scientific, investor and business development conferences:
- OktoberINVESTfest, 5th Annual Investors Conference
Date: 28 September 2016
Location: New York, USA
Dave Lemus, Medigene's COO, will give a company presentation.
- Adoptive T-Cell Therapy Summit
Date: 10 - 11 October 2016
Location: London, UK
Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will give a talk on the topic: "Mind the gap and fill the need: TCR cell therapies for patients with different MHCs and diverse forms of cancer."
- Osaka Partnering / BioJapan 2016
Date: 11 - 14 October 2016
Location: Osaka and Yokohama, Japan
- Forum Gesundheitsindustrie Baden-Württemberg
Date: 13 October 2016
Location: Heidelberg, Germany
Dr. Dr. Olav Zilian, Medigenes SVP Corporate Development
will give a talk on the topic: "Innovative T-cell therapy with Medigene's TCR platform ".
- 6. Equity Forum 2016 on Cancer Immunotherapy
Date: 26 October 2016
Location: Heilbronn, Germany
Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will hold a presentation on the latest developments in the field of immunotherapies.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
For more information, please visit www.medigene.com (http://www.medigene.com)
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com (mailto:investor@medigene.com)
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com (mailto:investor@medigene.com)). We will then delete your address from our distribution list.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire
--- End of Message ---
Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
